In an interview with CNBC-TV18, Omkar P Herlekar, MD of Lasa Supergenerics spoke about the latest happenings in his company and sector.
The company manufactures benzimidazole class of active pharmaceutical ingredients (APIs).
Capex will be happening on a proportionate basis, he said.
APIs are bound by foods and drug administration (FDA) regulations and the process to get approvals is tedious, he added.
According to him, regulatory risk is the only risk that the business faces.
Right now, we are registered with the Indian Drug Agency and we have filed our DMFs in various countries which includes Europe also, said Herlekar.
For full interview, watch accompanying video...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
